In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Dilution Necessary: The Promise of Project Financing

Executive Summary

Project financing, claim its proponents-in particular Symphony Capital-offers an alternative to highly dilutive equity offerings, preserving the upside from the development of a successful product for the biotech. That's true, though this expensive capital isn't for everyone. Yet as Big Pharma's productivity challenge deepens, project financing is helping to swing the balance of power further towards small companies.

Related Content

Symphony's Project Financing Model Adapts
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Private Equity Comes to Discovery
Generics Attract Royalty Funding Options Too
Will a New Accounting Change Cut Acquisition Values?
MGI Moves Into Acute Care with Guilford Acquisition
Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists
Exelixis/GSK: Using Project Financing to Accelerate R&D
Feeding the Machine: Exelixis Buys X-Ceptor
Symphony & Guilford Try Out Project Financing


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts